Glenmark Pharmaceuticals, an India-based global pharmaceutical company, is hiring at its pharmaceutical manufacturing facility in the Union County community of Monroe, outside Charlotte.
In 2014, Glenmark Pharmaceuticals Ltd. purchased the 15-acre site for its first North American manufacturing facility. It has spent some $18 million to set up its drug manufacturing plant and train staff to work in the factory, an existing 102,000-square-foot building in the Monroe Corporate Center near the Charlotte-Monroe Executive Airport.
Glenmark, headquartered in Mumbai, now employs 82 people and has 37 job opportunities available, according to company spokesperson An Phan.
The company’s website lists 16 of the positions, including research scientists, technicians, quality control specialists, a utility mechanic and others.
Phan said Glenmark also recently agreed to purchase an additional five acres of land adjacent to the existing building “to facilitate additional manufacturing capacity.”
In December 2016 Glenmark received approval from the Drug Enforcement Administration (DEA) to manufacture Schedule II controlled substances. Phan said Glenmark is currently working with the U.S. Food and Drug Administration to get approval to manufacture commercial batches.
When the company purchased the Monroe site, Glenn Saldanha, chairman and managing director, said it would initially produce oral solid dermatology, hormone replacement and cancer drugs, and later add injectable and topical formulations to its production line.
Glenmark, best known in the U.S. for its generic drugs, has 14 plants in four countries — India, Brazil, Argentina and the Czech Republic.
Glenn Saldanha’s father Gracias, founded the publicly traded company. The elder Saldanha died in 2012.
(C) N.C. Biotechnology Center
